insurance changes for glp-1 Lost coverage? What to do next GLP-1 Trends: Access & Shortages,

[10] [23] Regular monitoring and open communication with your healthcare team ensure that any concerning symptoms are evaluated promptly

Tirzepatide tends to be the better fit when: the goal is more significant weight loss (15 percent or more of body weight), the patient has type 2 diabetes with A1C above target on prior therapies, prior single-pathway GLP-1 use produced limited results, or the patient tolerated GLP-1s reasonably well and wants a stronger next step

Restraint Regulatory & Promotional Restrictions Regulatory and promotional restrictions act as a significant restraint for the GLP-1 market because they prohibit surrogate marketing, such as disease awareness campaigns, ban direct-to-consumer advertising, and mandate strict prescriptions

Multidistrict Litigation 3094 MDL 3094 refers to a multi-district litigation case consolidated in the Eastern District of Pennsylvania Federal Court against drug manufacturers Novo Nordisk (Ozempic, Wegovy, and Rybelsus) and Eli Lilly and Company (Trulicity and Mounjaro)